Transcriptional elongation is critical for gene expression regulation during embryogenesis. The super elongation complex (SEC) governs this process by mobilizing paused RNA polymerase II (RNAP2). Using exome sequencing, we discovered missense mutations in AFF4, a core component of the SEC, in three unrelated probands with a new syndrome that phenotypically overlaps Cornelia de Lange syndrome (CdLS) that we have named CHOPS syndrome (C for cognitive impairment and coarse facies, H for heart defects, O for obesity, P for pulmonary involvement and S for short stature and skeletal dysplasia). Transcriptome and chromatin immunoprecipitation sequencing (ChIP-seq) analyses demonstrated similar alterations of genome-wide binding of AFF4, cohesin and RNAP2 in CdLS and CHOPS syndrome. Direct molecular interaction of the SEC, cohesin and RNAP2 was demonstrated. These data support a common molecular pathogenesis for CHOPS syndrome and CdLS caused by disturbance of transcriptional elongation due to alterations in genome-wide binding of AFF4 and cohesin.
A r t i c l e s Transcriptional regulation during embryogenesis is of paramount importance in determining the precise temporospatial gene expression pattern. Recent evidence suggests that such transcriptional control is mainly achieved by regulation of transcriptional elongation 1 . Approximately 50 bp after transcriptional initiation, RNAP2 pauses in genes whose expression is mainly controlled at the elongation phase. For this transcriptional pausing, NELF (negative elongation factor) and DSIF (DRB sensitivity-inducing factor, a heterodimer of SPT4 and SPT5) are required 2 . Serine residues located within the C-terminal heptapeptide repeats of RNAP2 undergo phosphorylation modifications during gene transcription. Ser5-phosphorylated RNAP2 (RNAP2 Ser5ph) is enriched at the promoter-proximal region, and Ser2 phosphorylation occurs after transcriptional elongation starts. Therefore, Ser2-phosphorylated RNAP2 (RNAP2 Ser2ph) is regarded as actively elongating RNAP2 (ref. 3) . Mobilization of the paused RNAP2 machinery is governed by the SEC, which comprises multiple proteins including AFF4, ELL2 and positive transcription elongation factor b (P-TEFb), which is a heterodimer of CDK9 and cyclin T1 (ref. 4 ). CDK9 phosphorylates the Ser2 residue of RNAP2 to initiate transcriptional elongation 3 .
As many multiple-congenital-anomaly genetic conditions are due to disruption of proper transcriptional processes during embryogenesis, disruption of the transcriptional elongation process would be a likely pathogenic mechanism for developmental disorders. However, no causal links have been identified thus far. Through the characterization of a new genetic disorder caused by gain-of-function mutations in the AFF4 gene, encoding a key component of the SEC, we have established a link between the dysregulated transcription observed among disorders of cohesin function (collectively termed 'cohesinopathies') and disruption of RNAP2 elongation, caused by altered genome-wide binding of AFF4 and cohesin.
RESULTS

A new genetic disorder caused by AFF4 missense mutations
Germline mutations of cohesin complex structural and regulatory components cause CdLS (MIM 122470, 300590, 610759, 614701 Germline gain-of-function mutations in AFF4 cause a developmental syndrome functionally linking the super elongation complex and cohesin us to classify this as a new clinical entity ( Supplementary Table 1 ). We propose 'CHOPS syndrome' as an acronym to describe this new genetic disorder: C for cognitive impairment and coarse facies, H for heart defects, O for obesity, P for pulmonary involvement and S for short stature and skeletal dysplasia.
The striking phenotypic similarities among the three unrelated probands, all born to unaffected, non-consanguineous parents, led us to hypothesize that their clinical features were likely the result of a detrimental germline de novo mutation in the same gene. To test this hypothesis, we performed exome sequencing on these three probands. Each proband had 414 (CHOPS T254A), 720 (CHOPS R258W) and 725 (CHOPS T254S) rare deleterious mutations (nonsynonymous, protein-truncating, deletion, duplication or splice-site mutations). Exome statistics are listed in Supplementary Table 2 . Among these, we identified variants in 16 genes that were common to all probands. However, the variants in 14 genes were also present in in-house control samples, arguing against causality. We further scrutinized variants in the remaining two genes, AFF4 and ZFHX3. We confirmed the genetic variants of AFF4 and ZFHX3 by Sanger sequencing. All of the missense mutations found in AFF4 (c.760A>G (p.Thr254Ala), c.761C>G (p.Thr254Ser) and c.772C>T (p.Arg258Trp)) were de novo (not present in the six biological parents of the three probands) ( Fig. 1b and Supplementary Fig. 1 ). All three missense mutations mapped to the ALF (AF4-LAF4-FMR2) homology domain of AFF4, and these missense mutations altered highly evolutionarily conserved amino acids ( Fig. 1b) . All of the identified ZFHX3 variants were inherited from one of the parents of each proband (all of whom were unaffected). We confirmed paternity using STS markers in all 
Figure 2
Disease mechanism of CHOPS syndrome. (a) Decreased proteosomal degradation of mutant AFF4 in HEK293T cells. The protein blot demonstrates the disappearance of wild-type (WT) AFF4 bands with the addition of vector encoding SIAH1; such disappearance was not observed in HEK293T cells overexpressing mutant AFF4. The numbers beneath the AFF4 bands indicate signal intensity normalized to the band intensity of the AFF4-only condition for each category and to α-tubulin levels. (b,c) Expression levels of the MYC and JUN genes in patient-derived skin fibroblasts and the HEK293T cell line with AFF4 overexpression. GM01652, GM02036 and GM08398 are control fibroblast cell lines. Elevation of MYC and JUN expression was observed in CHOPS syndrome skin fibroblast (b) and the HEK293T AFF4 overexpression model (c). MYC and JUN expression was normalized against TBP levels. Data represent means ± 2 s.d. **P < 0.01, ***P < 0.001, two-tailed t test; n = 3 technical replicates per group. Empty, empty expression vector control. npg A r t i c l e s three probands. Screening of an additional 25 probands with atypical features of CdLS failed to identify mutations in the AFF4 gene. However, none of these probands exactly fit the CHOPS syndrome phenotype, indicating that mutations in this gene are highly correlated with the specific phenotype as characterized by the three patients described here. Collectively, these data support the hypothesis that missense mutations affecting the ALF homology domain of AFF4 cause CHOPS syndrome.
Mechanism of AFF4 mutations leading to CHOPS syndrome
A missense mutation affecting the ALF homology domain of Aff1 (also known as Af4) was reported in the robotic mouse, an ataxia mouse model created by N-ethyl-N-nitrosourea (ENU) mutagenesis 10 . The pathogenetic mechanism of this missense mutation is a gain-of-function effect due to decreased clearance of the protein by SIAH1 ubiquitin E3 ligase 11 . Given the vicinity of the location of the missense mutations in our probands to that described in the robotic mouse, we hypothesized that the missense mutations found in the three probands would likewise disrupt ubiquitination-dependent proteasomal degradation of the AFF4 protein. To test this hypothesis, we created an AFF4 and SIAH1 overexpression model using HEK293T cells. When an expression vector for wild-type AFF4 was transfected with an expression vector for SIAH1, the amount of AFF4 protein was markedly decreased; however, constructs for AFF4 containing the missense substitutions found in the three CHOPS syndrome probands showed hindered degradation of AFF4 with SIAH1 overexpression (Fig. 2a ). The addition of MG132, which is a proteosomal degradation inhibitor, resulted in the recovery of AFF4 bands.
Several genes including MYC and JUN have been identified as direct transcriptional targets of AFF4 (ref. 12) . We confirmed upregulation of MYC and JUN expression in patient-derived skin fibroblast samples by quantitative RT-PCR, although one proband with an AFF4 p.Arg258Trp alteration had a normal level of JUN expression ( Fig. 2b) . We also evaluated the expression levels of MYC and JUN in HEK293T cells transfected with overexpression vectors for AFF4. With wildtype AFF4 overexpression, the expression levels of MYC and JUN increased, confirming that these genes are downstream targets of the AFF4 protein. Overexpression of the mutant AFF4 constructs resulted in stronger activation of MYC expression. Without coexpression of SIAH1, the difference between wild-type and mutant AFF4 overexpression was minimal; however, with the addition of SIAH1 overexpression, the expression difference between the wild-type and mutant AFF4 constructs increased both for MYC and JUN (Fig. 2c) .
Because the SEC has an important role in the precise regulation of the immediate gene responses to various stimuli such as heat shock, retinoic acid or serum 1, 4 as well as in developmental regulation, we evaluated the effects of the AFF4 missense mutations on the immediate gene response using patient-derived skin fibroblast cell lines. These cell lines demonstrated upregulation of the FOS and EGR1 genes, which was comparable to that in control cell lines, upon serum stimulation (Supplementary Fig. 2) . Therefore, the proband-derived cell lines did not demonstrate an impaired response to serum stimulation with regard to the gene expression levels of FOS and EGR1, and mutant cells still maintained the capacity to mount a response to various stimuli.
Transcriptome analysis of CHOPS syndrome
Because of the critical role of the SEC in transcriptional regulation, we looked for abnormalities in global gene expression. We performed genome-wide expression profiling using Affymetrix U133 Plus 2.0 arrays on patient-derived skin fibroblast cell lines. We used two patient-derived samples (CHOPS T254A and CHOPS T254S) and three age-and sex-matched control samples, with all samples run in duplicate. We did not use the CHOPS R258W cell line owing to the lack of an appropriate ancestry-matched control cell line. Using a false discovery rate (FDR) cutoff of 0.2, we identified 288 genes downregulated and 445 genes upregulated in patient-derived samples relative to control samples ( Supplementary Fig. 3 and Supplementary  Table 3 ). Gene ontology term analysis using DAVID showed that the upregulated genes were enriched for homeobox proteins, skeletal system development/morphogenesis and anterior/posterior pattern formation, as well as embryonic organ development/morphogenesis, and that the downregulated genes were enriched for actin-binding proteins and extracellular matrix components ( Supplementary  Table 4 ). Previously, Luo et al. reported the results of AFF4 ChIP-seq and RNA sequencing (RNA-seq) after knockdown by small interfering RNA (siRNA) of AFF4 (ref. 12) . Combining the data reported by Luo et al., we selected seven genes as probable direct targets of AFF4, owing to the presence of an AFF4 peak near their promoter regions and downregulation of their expression levels upon AFF4 knockdown. All seven target genes were upregulated by 9 to 127% (mean = 48.9%) in skin fibroblasts from patients with AFF4 mutations in comparison to control samples ( Table 1 and Supplementary Fig. 4) . The upregulation of five of these genes was statistically significant: MYC, JUN, TMEM100, ZNF711 and FAM13C. These observations further support the notion that AFF4 mutations render gain-of-function effects.
Transcriptome similarities between CHOPS syndrome and CdLS
Given the phenotypic similarities between the three CHOPS syndrome probands with AFF4 mutations and individuals with CdLS, we compared the gene expression pattern of skin fibroblast samples with AFF4 mutations to those from CdLS probands with NIPBL frameshift mutations using the Affymetrix Human Gene 2.0 ST array. We observed a general positive correlation (Pearson's correlation coefficient = 0.34, P < 1 × 10 −300 ) for the gene expression patterns of CHOPS syndrome and CdLS (Fig. 3a) . We identified the top 250 most dysregulated (overexpressed and underexpressed) genes for these diagnoses. Expression levels of up-and downregulated genes were similar for the CdLS probands and the probands with AFF4 mutations (Fig. 3b,c) . Likewise, genes whose expression was downregulated in CdLS were similarly underexpressed in the probands with Group means are the average expression levels of genes measured by microarray, after normalization and log 2 transformation. The processed measurements were compared between groups by the SAM method to generate the P values, and non-log-transformed measurements were used to calculate the percentage expression change between groups. Details are given in the Online Methods.
npg
A r t i c l e s AFF4 mutations. Dysregulated genes in CHOPS syndrome demonstrated a similar expression pattern as observed in the samples from CdLS probands (Fig. 3b,c Table 5 ).
We observed positive correlation between transcriptional changes in CHOPS syndrome and CdLS ( Supplementary Fig. 5 ), as we did for primary cultured cells. We scored 302 upregulated genes and 216 downregulated genes in CHOPS syndrome (Supplementary Fig. 5b,c and Supplementary Table 6 ). Of the 78 upregulated genes and 220 downregulated genes in CdLS, 30 and 72 genes, respectively, showed significantly similar expression tendencies to those observed in CHOPS syndrome. Although the CHOPS R258W sample did not show overexpression of JUN in quantitative RT-PCR ( Fig. 2b) , the profile of dysregulated genes was very similar for CHOPS R258W in comparison to CHOPS T254A and CHOPS T254S ( Supplementary Fig. 5d ).
Chromatin accumulation of AFF4 in CHOPS syndrome
With the confirmation that the missense mutations found in the three CHOPS syndrome probands caused decreased clearance of mutated AFF4 protein due to acquired resistance to SIAH1-mediated proteasomal degradation, we analyzed the amount of chromatin-associated SEC component in the CHOPS syndrome cell lines. The amount of AFF4 protein in patient-derived skin fibroblasts was elevated, supporting the suggestion that the missense mutations found in these probands result in a more stable AFF4 protein (Fig. 4a) . The mRNA levels of AFF4 were comparable between proband and control samples ( Supplementary Fig. 6a ). In the samples from probands, the wild-type and mutant alleles were expressed in almost equal amounts (Supplementary Fig. 6b ). We further analyzed the amount of chromatin-associated AFF4, ELL2 and CDK9 in CHOPS syndrome cell lines and found that accumulation of AFF4 mainly occurred on the chromatin fraction in the CHOPS syndrome cell lines (Fig. 4b) .
The increase in AFF4 accumulation in CHOPS syndrome proband CHOPS T254A was due to the mutant AFF4 allele, as the amount of CdLS  GM02036  GM02036  CHOPS T254S  CHOPS T254S  CHOPS T254S  CHOPS T254A  CHOPS T254A  CHOPS T254A  CHOPS T254A AFF4 null  CHOPS T254A AFF4 null  CHOPS T254A AFF4 null  CHOPS T254A mut del  CHOPS T254A mut del  CHOPS T254A npg A r t i c l e s AFF4 protein was clearly decreased in cell lines where the mutated AFF4 allele was deleted ( Fig. 4b and Supplementary Fig. 7) . The amount of other SEC components such as ELL2 and CDK9 did not show major alterations in the chromatin fraction of the CHOPS syndrome cell lines relative to control cells. The CdLS cell line with an NIPBL frameshift mutation (CDL006) did not show elevation in the amounts of any of these proteins (Fig. 4b) .
Genome-wide chromatin binding of AFF4, RNAP2 and cohesin
To better understand the molecular mechanism leading to the similar transcriptional profiles for CHOPS syndrome and CdLS, we evaluated the genome-wide binding patterns of AFF4, elongating RNAP2, paused RNAP2, SPT5 and the cohesin subunit RAD21 by performing ChIP-seq ( Supplementary Table 7 ). To understand the shared characteristics of CdLS and CHOPS syndrome, we focused on differentially expressed genes in these two syndromes compared with a cell line from a healthy control.
Overall, downregulation and upregulation of genes at the level of RNA correlated well with increasing or decreasing chromatin binding levels of RNAP2, elongating RNAP2 (Ser2ph), paused RNAP2 (Ser5ph) and SPT5 in both CdLS and CHOPS syndrome (Supplementary Fig. 8 ). AFF4 binding around the transcription start site (TSS) was elevated both in the CHOPS syndrome and CdLS samples relative to the control sample among the transcriptionally upregulated genes (Supplementary Fig. 9 ). In contrast, among transcriptionally downregulated genes, we did not observe such enhanced TSS binding of AFF4 (Supplementary Fig. 9 ). However, in neither syndrome could we find a correlation between changes in AFF4 binding and transcription (Supplementary Fig. 10) . Interestingly, we observed an increase in RAD21 binding in comparison to the control at the TSSs of upregulated genes and the opposite effect at the TSSs of downregulated genes (Supplementary Fig. 9 ).
Molecular interactions among the SEC, cohesin and RNAP2
These findings prompted us to examine the physical interaction of the SEC, cohesin and RNAP2 (Fig. 5) . In HeLa cell lysate, immunoprecipitation with an antibody to STAG1 (SA1) yielded positive immunoblot bands for various SEC components, including AFF4, ELL2, cyclin T1 and CDK9; however, we did not observe such interactions with an antibody to STAG2 (SA2) (Fig. 5a) . Furthermore, we found that RNAP2 forms a complex with SMC1 and STAG1 but not with STAG2 in HeLa cell lysate (Fig. 5b) . Phosphorylated forms of RNAP2 were preferentially enriched in the coimmunoprecipitated fraction with STAG1 but not STAG2. Addition of elongation inhibitors such as DRB (5,6-dichlorobenzimidazole 1-β-d-ribofuranoside) and flavopiridol, which is a CDK9 kinase inhibitor, decreased the amount of both RNAP2 Ser2ph and Ser5ph precipitated with STAG1. Therefore, the RNAP2 interacting with STAG1 is primarily the elongating form of RNAP2.
DISCUSSION
Through the identification of gain-of-function mutations in AFF4 as the cause of a new syndrome consisting of a highly conserved pattern of features that we have termed CHOPS syndrome, we demonstrate that an altered RNAP2 distribution and resultant transcriptional elongation abnormalities underlie the transcriptional dysregulation of CHOPS syndrome as well as CdLS.
CHOPS syndrome represents the first human developmental disorder caused by germline mutations in an SEC component, although synonymous mutations were previously suggested to correlate with autism in two individuals 13, 14 . AFF4 is a scaffold protein comprising the core component of the SEC. In the probands reported here, the missense mutations create a resistance to ubiquitinationdependent proteasomal degradation, resulting in excessive amounts of accumulation of mutant AFF4 protein. This persistence of AFF4 protein in turn results in an altered genomic distribution of AFF4 and leads to the unique transcriptome pattern of CHOPS syndrome. The transcriptomic effects of the AFF4 gain-of function mutations seen in CHOPS syndrome were opposite to those observed in AFF4 knockdown experiments, confirming that the disease mechanism of these mutant AFF4 proteins is a gain of function rather than haploinsufficiency or a dominant-negative effect. In addition, the phenotype of the CHOPS syndrome probands is different from that of the Aff4 knockout mouse as well as human subjects with genomic deletions encompassing the AFF4 gene, lending further support to a gain-offunction effect 15, 16 . Comparing the AFF4 binding patterns among the upregulated and downregulated genes, an alteration was seen only in the upregulated genes, further supporting the notion that the primary effect of the AFF4 mutations found in CHOPS syndrome is gain of function, leading to transcriptional activation (Supplementary Fig. 11) . The fundamental role of transcriptional elongation in the control of gene expression during embryogenesis has recently begun to be better understood 1 . Therefore, CHOPS syndrome can be regarded as a multiple-congenital-anomaly syndrome caused by disturbance of the transcriptional elongation process.
Although accumulation of AFF4 was observed for the transcriptionally activated genes in CHOPS syndrome and CdLS, there was no correlation between AFF4 ChIP-seq and RNA-seq or RNAP2 Ser2ph ChIP-seq in either syndrome (Supplementary Fig. 10) . This finding suggests that AFF4 controls gene expression for only a subset of AFF4-bound genes, which is consistent with previously reported data by Luo et al., demonstrating that the knockdown of AFF4 leads npg to downregulation of expression for only a very small subset of genes (seven genes) among those that harbor an AFF4 ChIP-seq peak around the TSS in the HEK293T cell line 12 . In CHOPS syndrome and CdLS, transcriptional alterations are more likely seen for the genes where expression is mainly regulated by the transcriptional elongation step. Similar findings were reported for other transcription elongation controller molecules such as DSIF and NELF 2,17 .
In the CHOPS syndrome fibroblast cell lines, even with the massive accumulation of AFF4 in the chromatin fraction, the amount of other SEC components (ELL2 and CDK9) remained unchanged. However, the amount of these proteins forming the SEC is likely to be increased, given that the primary effect seen in CHOPS syndrome is activation of AFF4 target genes. CDK9 is known to form a complex with BRD4 or 7SK RNA and HEXIM outside of the SEC, as well as existing as a free CDK9 molecule [18] [19] [20] [21] . Therefore, the amount of CDK9 forming the SEC is likely to be increased with the concurrent decrease in the amount of CDK9 forming complexes with BRD4 or 7SK RNA and HEXIM or free CDK9 in the nucleus. This speculation is supported by the fact that transfection with construct for AFF4 alone exerted transcriptional activation effects on SEC target genes such as MYC and JUN, even without concurrent overexpression of other SEC components (Fig. 2c) .
AFF4 is expressed in fetal brain, lung and heart and in adult brain, heart, skeletal muscle and pancreas 22 . It is very intriguing that all CHOPS syndrome probands manifested with chronic lung disease, given the strong expression of AFF4 in fetal lung. In addition, AFF4 is implicated in regulation of appetite, as hypothalamic AFF4 expression is upregulated upon fasting 23 . Therefore, it is possible that gainof-function mutations in AFF4 lead to increased appetite, resulting in the obesity seen in CHOPS syndrome probands.
Although CHOPS syndrome and CdLS are clinically recognizable as distinct entities, there is some phenotypic overlap between these two diagnoses suggesting a common underlying pathogenesis. Given the apparently divergent molecular etiologies of each, we were somewhat surprised to discover striking similarities in the transcriptomic profiles of CHOPS syndrome and CdLS.
Effects on gene transcription by mutated cohesin components or regulators have been proposed as the pathogenic mechanism of CdLS, establishing a critical role for cohesin in transcriptional regulation 24 . One mechanism by which cohesin controls transcription is through the creation of looping DNA structures that allow for physical interactions between distal regulatory elements and promoter regions 25, 26 . However, the exact mechanism by which cohesin regulates transcription remains poorly understood.
We discovered that both CHOPS syndrome and CdLS display a similar disruption in the behavior of AFF4 and RAD21. Interestingly, the genes whose expression is significantly increased in CHOPS syndrome and CdLS demonstrate elevated AFF4 binding. In combination with the finding that similar sets of genes are upregulated and downregulated in CdLS and CHOPS syndrome, we can conclude that the altered genome-wide distribution of AFF4 binding affects cohesin binding in CHOPS syndrome, with the inverse relationship being true in CdLS (where the altered genome-wide distribution of cohesin affects AFF4 binding).
Furthermore, as a molecular link between CHOPS syndrome and CdLS, we demonstrated a physical interaction between the SEC, the STAG1-cohesin complex and RNAP2. This represents the first demonstration, to our knowledge, of such a physical interaction not only between the SEC and cohesin but also between cohesin and RNAP2. Recently, functional differences between the STAG1 and STAG2 components of cohesin have started to emerge. Previously, the Stag1 knockout mouse model demonstrated the importance of STAG1 in transcriptional regulation, as well as a critical function in chromosomal segregation 27, 28 . Our results point to an important role for STAG1 in the pathogenesis of CdLS.
A role for cohesin in transcription elongation has previously been proposed. Cohesin selectively binds genes in which RNAP2 pauses just downstream of the TSS, and it was hypothesized that cohesin facilitates transition of paused RNAP2 to elongation 24, 29 . This role of cohesin in transcriptional elongation is likely facilitated by NIPBL-MAU2, with AFF4 and the SEC mediating its effect. Recently, cohesin loaders (NIPBL-MAU2) were shown to be important in maintaining nucleosome-free regions in yeast models, and it was hypothesized that derangements of nucleosome positioning cause transcriptional disturbance in cohesinopathies 30 . Our observation suggests that NIPBL and MAU2 also have a role in the transcriptional elongation process, which requires the presence of paused RNAP2 at gene promoters.
In summary, we report the identification of a new genetic disorder, CHOPS syndrome, caused by mutations in AFF4 and demonstrate that altered genome-wide binding of AFF4 leading to RNAP2 gene body accumulation underlies the transcriptional abnormalities observed. We also demonstrate a molecular link between CHOPS syndrome and CdLS and implicate cohesin in transcriptional elongation. These observations underscore the importance of proper proximal pausing of RNAP2 as a crucial regulator of gene expression during human embryogenesis. 
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Quantitative RT-PCR. Extracted RNA samples were also used for quantitative RT-PCR. RNA was reverse transcribed with TaqMan Reverse Transcription Reagents (Life Technologies), and synthesized cDNA was used for quantitative PCR analysis by droplet digital PCR system (QX100, Bio-Rad) 35, 36 . Gene expression was analyzed using TaqMan gene expression assay probes, including AFF4 Hs00232683_m1, MYC Hs00153408_m1, JUN Hs01103582_s1, FOS Hs04194186_s1 and EGR1 Hs00152928_m1 (Life Technologies). Internal control probes used were TBP 4326322E and CYC 4326316E (Life Technologies). For allele-specific mRNA detection of AFF4, Custom TaqMan SNP Genotyping Assays (Life Technologies) were used, and TaqMan probes were designed for three AFF4 mutations found in CHOPS syndrome probands. Probe sequences are available on request. For serum stimulation, cells were cultured in serum-free medium for 2 d and were then either left untreated or treated with serum for 30 min before RNA extraction. Gene expression levels for the FOS and EGR1 genes, both of which were induced by serum stimulation, were measured by quantitative RT-PCR 1 .
RNA-seq analyses.
For total RNA-seq, we used immortalized skin fibroblast cell lines from CHOPS T254A (CDL444), CHOPS T254S (CDL160), CHOPS R258W, CDL006, GM01652, GM02036 and GM03348 (CHOPS R258W (CDL559): an 8-year-old African-American female with a p.Arg258Trp alteration). All samples were sequenced on the Illumina HiSeq 2500 platform as single-end 50-bp reads and mapped to the human genome (UCSC build hg19). Sequencing and mapping statistics are summarized in Supplementary Table 5 . Total RNA was extracted using TRIzol (Life Technologies) and Nucleospin RNA (Macherey-Nagel) following the manufacturers' instructions. The RNA-seq analysis was performed using TopHat version 2.0.8b 37 and Cufflinks version 2.1.1 (ref. 38) with the default parameter set. We applied Ensembl gene annotation (GRCh37) for both TopHat and Cufflinks. We considered protein-coding genes only, and gene-level expression values were estimated by fragments per kilobase of exon per million fragments mapped (FPKM) score. We obtained a total of 519 and 299 deferentially expressed genes for CHOPS syndrome and CdLS, respectively ( Supplementary Table 6 ).
ChIP-seq analyses. For ChIP-seq, we used immortalized skin fibroblast cell lines of CHOPS T254A (CDL444), CDL006 and GM2036 samples. Chromatin immunoprecipitation was performed as previously described 39 . Briefly, cells were cross-linked with 1% formaldehyde for 10 min. Soluble cell lysates were prepared by sonication or both MNase treatment and sonication. Lysates were then incubated with protein A or protein G Dynabeads (Life Technologies) conjugated with antibodies. Beads were washed, and bound fractions were eluted. After reversal of cross-linking for elutes and input samples, DNA was purified using the PCR purification kit (Qiagen). DNA from input and immunoprecipitation fractions was further sheared to an average size of approximately 150 bp by ultrasonication (Covaris), end repaired, ligated to sequencing adaptors and amplified according to the manufacturer's instructions (NEBNext ChIP-seq Library Prep Master Mix Set for Illumina; New England BioLabs). Sequenced reads were mapped to the human genome using Bowtie version 1.1.0 (ref. 40) , allowing two mismatches in the first 28 bases per read and outputting only uniquely mapped reads (-n2 -m1 option). Mapping statistics are summarized in Supplementary Table 7 . ChIP-seq analysis and visualization were performed using DROMPA version 2.5.3 (ref. 41) . To facilitate comparison of detected peaks between different ChIP-seq experiments, the number of mapped reads was normalized with the total number of mapped reads. To eliminate uncertain sites, we ignored regions with low mappability (mappability <0.3 for a 1-kb window). Scatter plots for RNAP2, AFF4 and SPT5 are shown in Supplementary Figures 8 and 10 . We applied CG command to normalize and count the mapped reads within each gene body region. Plotting of averaged reads around TSSs (Supplementary Fig. 9 ) was performed using PROFILE command. RefSeq gene annotation was obtained from the UCSC Genome Browser.
Genome editing. For the introduction of AFF4 deletion, the CRISPR/cas9 system was used 42 . gRNA and hCas9 vectors were purchased from Addgene. AFF4 exon 3 target sequence was introduced into an empty gRNA vector. The gRNA target sequence was ATGGGCCGCACATAGGCAG. AFF4 exon 3targeting gRNA vector and hCas9 plasmids were transfected into skin fibroblast cell lines using the Neon electroporation system (Life Technologies). After electroporation, single-cell cloning was performed. For each clone, the presence or absence of genome editing was confirmed by Sanger sequencing.
